Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nafagrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 15/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nafagrel SCHEMBL7274167 | 1.00 | TBXAS1 (0.59) | TBXAS1MEN1LMNAKMT2AMCHR1 | |
| Nafagrel SCHEMBL7301697 | 0.99 | TBXAS1 (0.60) | TBXAS1MEN1LMNAKMT2AMCHR1 | |
| Nafagrel SCHEMBL6570453 | 0.98 | TBXAS1 (0.61) | TBXAS1MCHR1CYP2B6CYP19A1 | |
| Hydrochloric Acid SCHEMBL10529625 | 0.96 | TBXAS1 (0.59) | TBXAS1MEN1LMNAKMT2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL10529618 | 0.96 | TBXAS1 (0.59) | TBXAS1MEN1LMNAKMT2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL10823706 | 0.94 | TBXAS1 (0.60) | TBXAS1MEN1LMNAKMT2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL10529572 | 0.90 | TBXAS1 (0.53) | TBXAS1MEN1LMNAKMT2A | |
| SCHEMBL10531273 | 0.88 | TBXAS1 (0.54) | TBXAS1 | |
| Hydrochloric Acid SCHEMBL10531196 | 0.84 | TBXAS1 (0.49) | TBXAS1LMNACYP19A1 | |
| SCHEMBL10532551 | 0.83 | TBXAS1 (0.50) | TBXAS1LMNACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5354770-A | Cardiovascular system disorders | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-10-11 | — | — | US | claimed |
| US-5354770-A | Cardiovascular system disorders | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0297593-B1 | TREATING AGENT FOR HEART FAILURE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-04-28 | — | — | EP | disclosed |
| EP-0298465-B1 | ANTIDIABETIC AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-02-17 | — | — | EP | disclosed |
| US-4942171-A | The compound, 6-(1-imidazolyl methyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid and salts thereof having antidiabetic activity | DAIICHI SEIYAKU CO., LTD. (JP) | 1990-07-17 | — | — | US | disclosed |
| US-4933349-A | IMIDAZOLYL, THIAZOLYL, OR PYRIOYL GROUP SUBSTITUTED AROMATIC ACIDS | DAIICHI SEIYAKU CO., LTD. (JP) | 1990-06-12 | — | — | US | disclosed |